Analysts at Baird upgraded DaVita HealthCare Partners Inc DVA from Neutral to Outperform.
The price target for DaVita HealthCare has been raised from $75.00 to $95.00.
DaVita HealthCare shares have gained 21.19 percent over the past 52 weeks, while the S&P 500 index has surged 13.28 percent in the same period.
DaVita HealthCare shares rose 0.60 percent to close at $83.91 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in